ZMH (63.71) at highest price since Lehman bankruptcy. This is notable given the substantial headwinds faced by medical-device companies from a slowdown in elective procedures and reimbursement cuts in Europe.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”